Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
52.68 USD | -1.14% | -4.82% | -16.27% |
04:13pm | Baird Adjusts Price Target on CRISPR Therapeutics to $52 From $46, Keeps Neutral Rating | MT |
08/05 | CRISPR Therapeutics AG Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-16.27% | 4.52B | |
+25.75% | 46.71B | |
+48.83% | 41.8B | |
-1.14% | 41.52B | |
-3.42% | 29.55B | |
+10.19% | 25.78B | |
-20.60% | 19.26B | |
+0.69% | 12.14B | |
-0.97% | 12.08B | |
+26.39% | 11.98B |
- Stock Market
- Equities
- CRSP Stock
- News CRISPR Therapeutics AG
- RBC Raises Price Target on CRISPR Therapeutics to $66 From $57 on Strengthened Balance Sheet, Casgevy Approval; Sector Perform, Speculative Risk Kept